Subscribe

Gastrointestinal Cancers

Nivolumab plus Ipilimumab Shows Promising Activity in the Neoadjuvant Setting for Patients with MSI/dMMR Oeso-Gastric Adenocarcinoma
By Wayne Kuznar
Gastrointestinal Cancers
June 2022, Vol 13, No 3
Treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) in the neoadjuvant setting plus adjuvant nivolumab resulted in a high rate of pathologic complete response (pCR) in patients with resectable microsatellite instability (MSI)/mismatch repair deficient (dMMR) oeso-gastric junction (OGJ) adenocarcinoma, according to findings from the GERCOR NEONIPIGA clinical trial, which were presented by Thierry André, MD, Professor, Medical Oncology, Sorbonne Université, Hôpital Saint Antoine, Paris, France, at the 2022 ASCO Gastrointestinal Cancers Symposium.
Read Article
Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer
By Wayne Kuznar
Gastrointestinal Cancers, ASCO 2021 Highlights
August 2021, Vol 12, No 4
Early results from the CheckMate-648 clinical trial, which evaluated the efficacy and safety of Opdivo (nivolumab), a PD-1 inhibitor, plus Yervoy (ipilimumab), a CTLA-4 inhibitor, or nivolumab plus chemotherapy, suggest a potential new standard of care for the first-line treatment of patients with advanced esophageal squamous-cell carcinoma (ESCC). These findings were presented at the ASCO 2021 virtual annual meeting by Ian Chau, MD, Consultant Medical Oncologist, Gastrointestinal and Haemato-Oncology, Royal Marsden Hospital, Sutton, United Kingdom, and lead investigator of the trial.
Read Article
Recent Progress in the Biomarker Landscape for Gastrointestinal Malignancies
By Nicholas J. Sarlis, MD, PhD, FACP
Gastrointestinal Cancers
June 2021, Vol 12, No 3
Gastrointestinal (GI) malignancies account for 26% of the global cancer incidence and 35% of all cancer-related deaths.1 There is an urgent need for new therapeutic options for patients with advanced disease beyond the standard, highly burdensome combinatorial approach of polychemotherapy, radiotherapy, and surgery.1 Recent advances in tumor molecular profiling are transforming the therapeutic landscape for patients with GI cancers, allowing for prognostication and predictive risk assessment, as well as more individualized regimens that can extend survival while minimizing the side effects that have long been associated with existing “legacy” treatment options.
Read Article
Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation
By Wayne Kuznar
ASCO, Gastrointestinal Cancers, Pancreatic Cancer
April 2020, Vol 11, No 2

San Francisco, CA—Platinum-based therapy represents a new standard of care in patients with pancreatic cancer and germline BRCA or PALB2 mutation, based on data reported at the 2020 Gastrointestinal Cancers Symposium. The findings were published simultaneously in the Journal of Clinical Oncology (O’Reilly EM, et al. J Clin Oncol. 2020 Jan 24. Epub ahead of print).

Read Article
Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation
By Wayne Kuznar
ASCO, Colorectal Cancer, Gastrointestinal Cancers
April 2020, Vol 11, No 2

San Francisco, CA—The combination of encorafenib (Braftovi) plus cetuximab (Erbitux), with or without binimetinib (Mektovi), improved the quality of life based on patient-reported assessments better than current standard of care in the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation, according to the BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium.

Read Article
FDA Grants Approval to Avapritinib for Patients with GIST
FDA Approvals, News & Updates, Gastrointestinal Cancers, In the News
Web Exclusives
The FDA approval of avapritinib marks the first time a drug has been approved specifically for patients with GIST harboring PDGFRA exon 18 mutations, which are involved in approximately 10% of GIST cases.
Read Article
New Clues to Mismatch Repair and PD-1/PD-L1 Status and Survival in Patients with Gastric or Esophageal Cancer
By Charles Bankhead
Gastrointestinal Cancers
Web Exclusives
San Francisco, CA—Understanding the complex relationship between the PD-1 receptor, its ligand 1 (PD-L1), and mismatch repair deficiency (dMMR) status may help to improve treatment outcomes in patients with resectable gastric and esophageal cancer, according to a retrospective tissue-based analysis.
Read Article

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.